Pancreatic Neoplasms

• 

  Subject Areas on Research

  • (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. 
  • 18F-FDG PET/CT Metabolic Tumor Volume and Intratumoral Heterogeneity in Pancreatic Adenocarcinomas: Impact of Dual-Time Point and Segmentation Methods. 
  • 18F-FDG-PET/CT therapy assessment of locally advanced pancreatic adenocarcinoma: impact on management and utilization of quantitative parameters for patient survival prediction. 
  • 25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance). 
  • 5,10-Methylenetetrahydrofolate reductase polymorphisms and the risk of pancreatic cancer. 
  • A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). 
  • A Collimator Setting Optimization Algorithm for Dual-Arc Volumetric Modulated Arc Therapy in Pancreas Stereotactic Body Radiation Therapy. 
  • A Four-Chemokine Signature Is Associated with a T-cell-Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer. 
  • A Gastric Glycoform of MUC5AC Is a Biomarker of Mucinous Cysts of the Pancreas. 
  • A PK2/Bv8/PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancer. 
  • A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. 
  • A Pilot Study Evaluating Serum MMP7 as a Preoperative Prognostic Marker for Pancreatic Ductal Adenocarcinoma Patients. 
  • A Quantitative Global Proteomics Approach Identifies Candidate Urinary Biomarkers That Correlate With Intraductal Papillary Mucinous Neoplasm Dysplasia. 
  • A challenge to the therapeutic nihilism of ESPAC-1. 
  • A cost analysis of a pancreatic cancer screening protocol in high-risk populations. 
  • A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. 
  • A matched case-control study of preoperative biliary drainage in patients with pancreatic adenocarcinoma: routine drainage is not justified. 
  • A morphological analysis endocrine tumour genesis in pancreas and anterior pituitary of AVP/SV40 transgenic mice. 
  • A multispecialty approach to the diagnosis and management of pancreatic cancer. 
  • A niche role for cancer exosomes in metastasis. 
  • A novel metric for quantification of homogeneous and heterogeneous tumors in PET for enhanced clinical outcome prediction. 
  • A novel model system for studying the double-edged roles of nitric oxide production in pancreatic cancer growth and metastasis. 
  • A novel, clinically relevant animal model of metastatic pancreatic adenocarcinoma biology and therapy. 
  • A p300/GATA6 axis determines differentiation and Wnt dependency in pancreatic cancer models. 
  • A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer. 
  • A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer. 
  • A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003. 
  • A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract. 
  • A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors. 
  • A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. 
  • A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer. 
  • A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. 
  • A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study. 
  • A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. 
  • A phase II trial of streptozotocin and adriamycin in advanced APUD tumors. 
  • A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. 
  • A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer. 
  • A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. 
  • A randomized comparison of EUS-guided FNA versus CT or US-guided FNA for the evaluation of pancreatic mass lesions. 
  • A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. 
  • A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. 
  • A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. 
  • A report of a gastrinoma localized preoperatively by endoscopic ultrasound only and a review of the approach to imaging in Zollinger-Ellison syndrome. 
  • A single institution's 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram. 
  • A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. 
  • A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma. 
  • A wolf in sheep's clothing: a non-functioning islet cell tumor of the pancreas masquerading as a microcystic (serous cystic) adenoma. 
  • ABO non-O type as a risk factor for thrombosis in patients with pancreatic cancer. 
  • ACR Appropriateness Criteria® Pancreatic Cyst. 
  • ACR Appropriateness Criteria® Staging of Pancreatic Ductal Adenocarcinoma. 
  • ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. 
  • ASO Author Reflection: Postoperative Chemotherapy for Nonmetastatic, Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinomas. 
  • ASO Author Reflections: Irreversible Electroporation for Locally Advanced Pancreatic Cancer. 
  • ASO Author Reflections: Long-Term Outcomes After Surgical Resection of Pancreatic Metastases from Renal Clear-Cell Carcinoma. 
  • ASO Author Reflections: Progression after Resection of Noninvasive or Microinvasive Intraductal Papillary Mucinous Neoplasms. 
  • ASO Author Reflections: Spatial Immunophenotyping of Intraductal Papillary Mucinous Neoplasm. 
  • ASO Visual Abstract: Multidimensional Immunophenotyping of Intraductal Papillary Mucinous Neoplasms Reveals Novel T Cell and Macrophage Signature. 
  • ATDC/TRIM29 phosphorylation by ATM/MAPKAP kinase 2 mediates radioresistance in pancreatic cancer cells. 
  • AURKA amplification, chromosome instability, and centrosome abnormality in human pancreatic carcinoma cells. 
  • Ablation of the locally advanced pancreatic cancer: An introduction and brief summary of techniques. 
  • Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. 
  • Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy. 
  • Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. 
  • Activation of RalA is critical for Ras-induced tumorigenesis of human cells. 
  • Activator protein-1 has an essential role in pancreatic cancer cells and is regulated by a novel Akt-mediated mechanism. 
  • Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines. 
  • Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin. 
  • Adenovirus-mediated expression of the catalytic subunit of glucose-6-phosphatase in INS-1 cells. Effects on glucose cycling, glucose usage, and insulin secretion. 
  • Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [seecomments]. 
  • Adipose Triglyceride Lipase (ATGL) Expression Is Associated with Adiposity and Tumor Stromal Proliferation in Patients with Pancreatic Ductal Adenocarcinoma. 
  • Adjuvant radiation therapy for distal pancreatic cancer: is there a role? 
  • Adjuvant radiotherapy in the treatment of invasive intraductal papillary mucinous neoplasm of the pancreas: an analysis of the surveillance, epidemiology, and end results registry. 
  • Adjuvant therapy for pancreatic cancer: an evolving paradigm. 
  • Adjuvant therapy for pancreatic cancer: current status and future directions. 
  • Adjuvant therapy for surgically resected pancreatic adenocarcinoma. 
  • Adjuvant therapy of pancreatic cancer. 
  • Advanced pancreatic cancer: a phase I-II trial of cisplatin, high-dose cytarabine, and caffeine. 
  • Advances in immunotherapy for pancreatic cancer: 2013. 
  • Advances in the diagnosis and treatment of adenocarcinoma of the pancreas. 
  • Advances in the management of pancreatic cystic neoplasms. 
  • Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. 
  • Allergies, obesity, other risk factors and survival from pancreatic cancer. 
  • Altered telomeres in tumors with ATRX and DAXX mutations. 
  • Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. 
  • Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. 
  • An Automated High-throughput Array Microscope for Cancer Cell Mechanics. 
  • An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204). 
  • An Interpretable Planning Bot for Pancreas Stereotactic Body Radiation Therapy. 
  • An adenovirus vector for efficient RNA interference-mediated suppression of target genes in insulinoma cells and pancreatic islets of langerhans. 
  • An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. 
  • An in vivo platform for translational drug development in pancreatic cancer. 
  • An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance). 
  • Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. 
  • Analysis on binary responses with ordered covariates and missing data. 
  • Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. 
  • Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models. 
  • Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model. 
  • Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model. 
  • Antidiabetic therapies affect risk of pancreatic cancer. 
  • Antigens of human pancreatic adenocarcinoma cells defined by murine monoclonal antibodies. 
  • Antioxidants and prevention of gastrointestinal cancers. 
  • Antitumor activity of epidermal growth factor receptor-related protein is mediated by inactivation of ErbB receptors and nuclear factor-kappaB in pancreatic cancer. 
  • Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells. 
  • Assessing the Financial Burden Associated With Treatment Options for Resectable Pancreatic Cancer. 
  • Assessment of pancreatic duct strictures. 
  • Association between hepatitis B virus and pancreatic cancer. 
  • Association of diabetes and perineural invasion in pancreatic cancer. 
  • Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome. 
  • Associations between genetic variants of KIF5B, FMN1, and MGAT3 in the cadherin pathway and pancreatic cancer risk. 
  • Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6. 
  • Atypical squamous epithelium in cytologic specimens from the pancreas: cytological differential diagnosis and clinical implications. 
  • Aurora-A and p16 polymorphisms contribute to an earlier age at diagnosis of pancreatic cancer in Caucasians. 
  • BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. 
  • Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. 
  • Bilateral diffuse uveal melanocytic proliferation associated with pancreatic carcinoma: a case report and literature review of this paraneoplastic syndrome. 
  • Biliary self-expandable metal stents do not adversely affect pancreaticoduodenectomy. 
  • Biobanking of human pancreas cancer tissue: impact of ex-vivo procurement times on RNA quality. 
  • Biomarkers for early detection and screening in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. 
  • Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. 
  • Body mass index and obesity- and diabetes-associated genotypes and risk for pancreatic cancer. 
  • Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. 
  • Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2. 
  • Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. 
  • Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. 
  • Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. 
  • Brachytherapy via a depot of biopolymer-bound 131I synergizes with nanoparticle paclitaxel in therapy-resistant pancreatic tumours. 
  • Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence? 
  • Breaking barriers for T cells by targeting the EPHA2/TGF-β/COX-2 axis in pancreatic cancer. 
  • Burden of pancreatic cancer and disease progression: economic analysis in the US. 
  • CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. 
  • CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. 
  • CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. 
  • CT Radiomic Features of Superior Mesenteric Artery Involvement in Pancreatic Ductal Adenocarcinoma: A Pilot Study. 
  • CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma. 
  • Cadherin 17 is frequently expressed by 'sclerosing variant' pancreatic neuroendocrine tumour. 
  • Can physician gestalt predict survival in patients with resectable pancreatic adenocarcinoma? 
  • Candidate DNA repair susceptibility genes identified by exome sequencing in high-risk pancreatic cancer. 
  • Carcinoid and chylous ascites: an unusual association. 
  • Carcinoma of the pancreas. Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody. 
  • Case records of the Massachusetts General Hospital. Case 20-2005. A 58-year-old man with locally advanced pancreatic cancer. 
  • Case report: chylous ascites and carcinoid tumors: possible association of two rare disorders. 
  • Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. 
  • Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. 
  • Cell cycle regulation of human pancreatic cancer by tamoxifen. 
  • Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. 
  • Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Treatment Does Not Predict Pathological Response and Survival in Resectable Pancreatic Ductal Adenocarcinoma. 
  • Chemoprevention of pancreatic cancer: ready for the clinic? 
  • Chemoradiation for localized pancreatic cancer: another perspective. 
  • Chemotherapy and intensity-modulated radiation therapy for locally advanced pancreatic cancer achieves a high rate of R0 resection. 
  • Choroidal metastatasis from a neuroendocrine tumor masquerading as choroidal melanoma. 
  • Cilia loss sensitizes cells to transformation by activating the mevalonate pathway. 
  • Circulating Thrombospondin-2 enhances prediction of malignant intraductal papillary mucinous neoplasm. 
  • Circulating vitamin D concentration and risk of seven cancers: Mendelian randomisation study. 
  • Clinical Data Prediction Model to Identify Patients With Early-Stage Pancreatic Cancer. 
  • Clinical Insights Into the Biology and Treatment of Pancreatic Cancer. 
  • Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review. 
  • Clinical criteria for integrated molecular pathology in intraductal papillary mucinous neoplasm: less is more. 
  • Clinical features and outcome of primary pancreatic lymphoma. 
  • Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. 
  • Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience. 
  • Clinical utility of positron emission tomography in the diagnosis and management of periampullary neoplasms. 
  • Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma. 
  • Clinicopathological data and treatment modalities for pancreatic vipomas: a systematic review. 
  • Code Abdomen: An Assessment Coding Scheme for Abdominal Imaging Findings Possibly Representing Cancer. 
  • Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance. 
  • Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. 
  • Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. 
  • Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. 
  • Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. 
  • Comment on "Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival With or Without Liver Treatment". 
  • Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker. 
  • Comparison of monoamine oxidase in golden hamster islets and insulinoma. 
  • Comparison of outcomes and the use of multimodality therapy in young and elderly people undergoing surgical resection of pancreatic cancer. 
  • Competing Mortality in Patients With Neuroendocrine Tumors. 
  • Complications of pancreaticoduodenectomy after neoadjuvant chemoradiation in patients with and without preoperative biliary drainage. 
  • Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. 
  • Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice. 
  • Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. 
  • Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. 
  • Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. 
  • Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model. 
  • Cooperation between transcription factor AP-1 and NF-kappaB in the induction of interleukin-8 in human pancreatic adenocarcinoma cells by hypoxia. 
  • Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer. 
  • Cross Validation of the Monoclonal Antibody Das-1 in Identification of High-Risk Mucinous Pancreatic Cystic Lesions. 
  • Current Controversy of Radiographic Surveillance of Patients With Branch-duct IPMN and Pancreatic Cysts: Commentary on: Ductal Carcinoma Arising in a Largely Unchanged Presumed Branch Duct IPMN After 10 Years of Surveillance. 
  • Current approaches and future strategies for pancreatic carcinoma. 
  • Current management of cystic neoplasms of the pancreas. 
  • Current perspectives on locally advanced pancreatic cancer. 
  • Current utility of staging laparoscopy for pancreatic and peripancreatic neoplasms. 
  • Cutaneous Metastasis of a Mucoepidermoid Carcinoma of the Pancreas: First Reported Case. 
  • Cyclopamine-loaded core-cross-linked polymeric micelles enhance radiation response in pancreatic cancer and pancreatic stellate cells. 
  • Cyst Fluid Analysis in Pancreatic Intraductal Papillary Mucinous Neoplasms. 
  • Cyst fluid interleukin-1beta (IL1beta) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas. 
  • Cystic Neoplasms of the Pancreas. 
  • Cystic duct patency in malignant obstructive jaundice. An ERCP-based study relevant to the role of laparoscopic cholecystojejunostomy. 
  • Cystic lesions of the pancreas: changes in the presentation and management of 1,424 patients at a single institution over a 15-year time period. 
  • Cystic lesions of the pancreas: selection criteria for operative and nonoperative management in 209 patients. 
  • Cystic pancreatic neuroendocrine tumors: a clinicopathologic study. 
  • Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. 
  • Cytotoxic chemotherapy for pancreatic cancer: Advances to date and future directions. 
  • DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. 
  • DNA adducts in human pancreatic tissues and their potential role in carcinogenesis. 
  • DNA adducts, genetic polymorphisms, and K-ras mutation in human pancreatic cancer. 
  • DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer. 
  • DNA mismatch repair network gene polymorphism as a susceptibility factor for pancreatic cancer. 
  • DNA profile components predict malignant outcomes in select cases of intraductal papillary mucinous neoplasm with negative cytology. 
  • DNA repair gene polymorphisms and risk of pancreatic cancer. 
  • DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease. 
  • Deciphering the mechanisms of tumorigenesis in human pancreatic ductal epithelial cells. 
  • Deep learning on time series laboratory test results from electronic health records for early detection of pancreatic cancer. 
  • Defining criteria for selective operative management of pancreatic cystic lesions: does size really matter? 
  • Defining morbidity after pancreaticoduodenectomy: use of a prospective complication grading system. 
  • Defining the learning curve for team-based laparoscopic pancreaticoduodenectomy. 
  • Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens. 
  • Delayed apoptosis allows islet β-cells to implement an autophagic mechanism to promote cell survival. 
  • Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? 
  • Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study. 
  • Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells. 
  • Detailed Analysis of Margin Positivity and the Site of Local Recurrence After Pancreaticoduodenectomy. 
  • Detection of 2-amino-1-methyl-6-phenylimidazo [4,5-b]-pyridine (PhIP)-DNA adducts in human pancreatic tissues. 
  • Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA. 
  • Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma. 
  • Detection of early-stage pancreatic adenocarcinoma. 
  • Detection of micrometastases in peritoneal washings of pancreatic cancer patients by the reverse transcriptase polymerase chain reaction. 
  • Detection of mutated c-Ki-ras in the bile of patients with pancreatic cancer. 
  • Detection of pancreatic tumors, image quality, and radiation dose during the pancreatic parenchymal phase: effect of a low-tube-voltage, high-tube-current CT technique--preliminary results. 
  • Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? 
  • Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: A Report from The Pancreatic Surgery Consortium. 
  • Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer. 
  • Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer. 
  • Diagnosis of pancreatic carcinoma: role of FDG PET. 
  • Diagnostic and therapeutic implications of a novel immunohistochemical panel detecting duodenal mucosal invasion by pancreatic ductal adenocarcinoma. 
  • Diagnostic protein discovery using liquid chromatography/mass spectrometry for proteolytic peptide targeting. 
  • Diagnostic protein discovery using proteolytic peptide targeting and identification. 
  • Dietary mutagen exposure and risk of pancreatic cancer. 
  • Differences in K-ras and p53 gene mutations among pancreatic adenocarcinomas associated with regional environmental pollution. 
  • Differential Cell Susceptibilities to KrasG12D in the Setting of Obstructive Chronic Pancreatitis. 
  • Differential expression and regulation of the glucokinase gene in liver and islets of Langerhans. 
  • Differentiating pancreatic lesions by microarray and QPCR analysis of pancreatic juice RNAs. 
  • Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry. 
  • Differing molecular pathology of pancreatic adenocarcinoma in Egyptian and United States patients. 
  • Digital spatial profiling of intraductal papillary mucinous neoplasms: Toward a molecular framework for risk stratification. 
  • Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study. 
  • Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. 
  • Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. 
  • Discrete and complementary mechanisms of protection of beta-cells against cytokine-induced and oxidative damage achieved by bcl-2 overexpression and a cytokine selection strategy. 
  • Distal pancreatectomy for isolated metastasis of endometrial carcinoma to the pancreas. 
  • Distal pancreatectomy: a single institution's experience in open, laparoscopic, and robotic approaches. 
  • Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. 
  • Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). 
  • Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? 
  • Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy? 
  • Dosimetric comparison of 6 MV and 15 MV single arc rapidarc to helical TomoTherapy for the treatment of pancreatic cancer. 
  • Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling. 
  • Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. 
  • Duodenocolic fistula due to adenocarcinoma of the pancreas. 
  • Dying tumor cells stimulate proliferation of living tumor cells via caspase-dependent protein kinase Cδ activation in pancreatic ductal adenocarcinoma. 
  • Dysplasia at the surgical margin is associated with recurrence after resection of non-invasive intraductal papillary mucinous neoplasms. 
  • EMT Molecular Signatures of Pancreatic Neuroendocrine Neoplasms. 
  • EUS and confocal endomicroscopic diagnosis of pancreatic acinar cell cystadenoma. 
  • EUS-guided FNA of pancreatic metastases: a multicenter experience. 
  • Early Medicaid Expansion and Cancer Mortality. 
  • Early Recurrence and Omission of Adjuvant Therapy after Pancreaticoduodenectomy Argue against a Surgery-First Approach. 
  • Early onset pancreatic malignancies: Clinical characteristics and survival associations. 
  • Education and imaging. Hepatobiliary and pancreatic: Recurrent pancreatitis caused by a solid pseudopapillary neoplasm of the pancreas. 
  • Effect of deep learning image reconstruction in the prediction of resectability of pancreatic cancer: Diagnostic performance and reader confidence. 
  • Effect of insulin-like growth factor gene polymorphisms alone or in interaction with diabetes on the risk of pancreatic cancer. 
  • Effect of intra-operative fluid volume on peri-operative outcomes after pancreaticoduodenectomy for pancreatic adenocarcinoma. 
  • Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. 
  • Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. 
  • Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. 
  • Effects of base excision repair gene polymorphisms on pancreatic cancer survival. 
  • Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. 
  • Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. 
  • Endoscopic ultrasound and computer tomography are inaccurate methods of classifying cystic pancreatic lesions. 
  • Endoscopic ultrasound-guided fine needle aspiration biopsy of the intrapancreatic accessory spleen: a report of 2 cases. 
  • Endoscopic ultrasound-guided fine-needle aspiration of intrathoracic and intra-abdominal spindle cell and mesenchymal lesions. 
  • Enhanced pancreatic cancer gene therapy by combination of adenoviral vector expressing c-erb-B2 (Her-2/neu)-targeted immunotoxin with a replication-competent adenovirus or etoposide. 
  • Enhancement of gemcitabine cytotoxicity in pancreatic adenocarcinoma through controlled release of nitric oxide. 
  • Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. 
  • Epidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels. 
  • Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer. 
  • Epidermal growth factor receptor-targeted therapy for pancreatic cancer. 
  • Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis. 
  • Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. 
  • Equivalent Treatment and Survival after Resection of Pancreatic Cancer at Safety-Net Hospitals. 
  • Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth. 
  • Establishment of three-dimensional cultures of human pancreatic duct epithelial cells. 
  • European evidence-based guidelines on pancreatic cystic neoplasms. 
  • Evaluation of new anticancer agents against human pancreatic carcinomas in nude mice. 
  • Evaluation of preoperative therapy for pancreatic cancer using a prognostic nomogram. 
  • Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. 
  • Exosomes in Pancreatic Cancer: from Early Detection to Treatment. 
  • Experimental animal models of pancreatic carcinogenesis and metastasis. 
  • Experimental method for the hyperthermic treatment of cells in tissue culture: initial application to pancreatic cancer cells. 
  • Expression of CD24, a Stem Cell Marker, in Pancreatic and Small Intestinal Neuroendocrine Tumors. 
  • Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. 
  • Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human gammadelta-T cells: implications in the design of gammadelta-T-cell-based immunotherapies for pancreatic cancer. 
  • Expression of reg/PSP, a pancreatic exocrine gene: relationship to changes in islet beta-cell mass. 
  • Extended resection for pancreatic adenocarcinoma. 
  • Extracellular matrix proteins and carcinoembryonic antigen-related cell adhesion molecules characterize pancreatic duct fluid exosomes in patients with pancreatic cancer. 
  • Extramedullary plasmacytoma of the pancreas. 
  • FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes. 
  • FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. 
  • FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. 
  • Factors regulating islet regeneration in the post-insulinoma NEDH rat. 
  • Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression. 
  • Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. 
  • Familial pancreatic cancer. 
  • Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. 
  • Fate of the remnant pancreas after resection of noninvasive intraductal papillary mucinous neoplasm. 
  • Feasibility and yield of screening in relatives from familial pancreatic cancer families. 
  • Feeding jejunostomy tube placement in patients undergoing pancreaticoduodenectomy: an ongoing dilemma. 
  • Fibrogenesis in pancreatic cancer is a dynamic process regulated by macrophage-stellate cell interaction. 
  • Fifty years of pancreas cancer care. 
  • Filamentous inclusions in acinar cell carcinoma of the pancreas. 
  • Fine-needle aspiration of pancreatic extramedullary plasmacytoma: possible confusion with islet cell tumor. 
  • Five year results of US intergroup/RTOG 9704 with postoperative CA 19-9 ≤90 U/mL and comparison to the CONKO-001 trial. 
  • Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. 
  • Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. 
  • Focal or diffuse "fullness" of the pancreas on CT. Usually benign, but EUS plus/minus FNA is warranted to identify malignancy. 
  • Foregut carcinoids: a clinical and biochemical analysis. 
  • Four-dimensional diffusion-weighted MR imaging (4D-DWI): a feasibility study. 
  • Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. 
  • Function of nuclear factor kappaB in pancreatic cancer metastasis. 
  • Functional and morphologic changes associated with insulinoma transplantation into diabetic rats. 
  • Functional expression of sodium-glucose transporters in cancer. 
  • Further characterization of the target of a potential aptamer biomarker for pancreatic cancer: cyclophilin B and its posttranslational modifications. 
  • GAIP interacting protein C-terminus regulates autophagy and exosome biogenesis of pancreatic cancer through metabolic pathways. 
  • GFRα1 released by nerves enhances cancer cell perineural invasion through GDNF-RET signaling. 
  • GLUT-2 gene transfer into insulinoma cells confers both low and high affinity glucose-stimulated insulin release. Relationship to glucokinase activity. 
  • GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma. 
  • GNAS sequencing identifies IPMN-specific mutations in a subgroup of diminutive pancreatic cysts referred to as "incipient IPMNs". 
  • Gastric neuroendocrine tumours from long-term proton pump inhibitor users are indolent tumours with good prognosis. 
  • Gastro-Enteric-Pancreatic Neuroendocrine Tumor Treatment: 177Lu-DOTATATE. 
  • Gastrointestinal carcinoids: characterization by site of origin and hormone production. 
  • Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. 
  • Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). 
  • Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. 
  • Gene therapy and pancreatic cancer. 
  • Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802). 
  • Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. 
  • Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes. 
  • Genetic variants in the liver kinase B1-AMP-activated protein kinase pathway genes and pancreatic cancer risk. 
  • Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk. 
  • Genetic variants of p21 and p27 and pancreatic cancer risk in non-Hispanic Whites: a case-control study. 
  • Genetic variants of the peroxisome proliferator-activated receptor (PPAR) signaling pathway genes and risk of pancreatic cancer. 
  • Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. 
  • Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. 
  • Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. 
  • Genomic FHIT analysis in RER+ and RER- adenocarcinomas of the pancreas. 
  • Geographical clustering of pancreatic cancers in the Northeast Nile Delta region of Egypt. 
  • Getting up groggy. 
  • Giant Pancreatic Myoepithelial Hamartoma in a Patient With Familial Insulin-Dependent Diabetes Mellitus. 
  • Global expression analysis of well-differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays. 
  • Glucose metabolism gene polymorphisms and clinical outcome in pancreatic cancer. 
  • Glucose metabolism gene variants modulate the risk of pancreatic cancer. 
  • Glutathione S-transferase gene polymorphisms and risk and survival of pancreatic cancer. 
  • Glycophase glass revisited: protein adsorption and cell growth on glass surfaces bearing immobilized glycerol monosaccharides. 
  • Going the Extra Mile: Improved Survival for Pancreatic Cancer Patients Traveling to High-volume Centers. 
  • Gossypol and an HMT G9a inhibitor act in synergy to induce cell death in pancreatic cancer cells. 
  • Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate. 
  • HLA-A0201 positive pancreatic cell lines: new findings and discrepancies. 
  • Haplotype of N-acetyltransferase 1 and 2 and risk of pancreatic cancer. 
  • Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells. 
  • Health-Related Quality of Life After Pancreatectomy: Results From a Randomized Controlled Trial. 
  • Hepatic arterial nodal metastases in pancreatic cancer: is this the node of importance? 
  • Hepatic micrometastases are associated with poor prognosis in patients with liver metastases from neuroendocrine tumors of the digestive tract. 
  • High levels of nucleolar expression of nucleolin are associated with better prognosis in patients with stage II pancreatic ductal adenocarcinoma. 
  • High-risk population in sporadic pancreatic adenocarcinoma: guidelines for screening. 
  • Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. 
  • Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. 
  • Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1). 
  • Hospital Volume and the Costs Associated with Surgery for Pancreatic Cancer. 
  • How Long Should Patients with Cystic Lesions of the Pancreas Be Followed? 
  • How the radiologist can add value in the evaluation of the pre- and post-surgical pancreas. 
  • Human Trial of a Genetically Modified Herpes Simplex Virus for Rapid Detection of Positive Peritoneal Cytology in the Staging of Pancreatic Cancer. 
  • Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomas. 
  • Hyaline globules in neuroendocrine and solid-pseudopapillary neoplasms of the pancreas: a clue to the diagnosis. 
  • ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer. 
  • Identification of novel predictive markers for the prognosis of pancreatic ductal adenocarcinoma. 
  • Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303). 
  • Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. 
  • Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas. 
  • Imaging Features of Premalignant Biliary Lesions and Predisposing Conditions with Pathologic Correlation. 
  • Imaging comparison of tubular and colloid pancreatic adenocarcinoma arising from intraductal papillary mucinous neoplasm on multidetector CT. 
  • Immunocytochemistry for SOX-11 and TFE3 as diagnostic markers for solid pseudopapillary neoplasms of the pancreas in FNA biopsies. 
  • Immunodiagnosis of tumors in vivo using radiolabeled monoclonal antibody A2B5. 
  • Immunohistochemical [corrected] detection of the alternate INK4a-encoded tumor suppressor protein p14(ARF) in archival human cancers and cell lines using commercial antibodies: correlation with p16(INK4a) expression. 
  • Immunohistochemical p16INK4a analysis of archival tumors with deletion, hypermethylation, or mutation of the CDKN2/MTS1 gene. A comparison of four commercial antibodies. 
  • Immunological consequences of transplanting rat insulinomas. 
  • Impact of Angiotensin Receptor Blocker Use on Overall Survival Among Patients Undergoing Resection for Pancreatic Cancer. 
  • Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States. 
  • Impact of laparoscopic staging in the treatment of pancreatic cancer. 
  • Impact of minimally invasive vs. open distal pancreatectomy on use of adjuvant chemoradiation for pancreatic adenocarcinoma. 
  • Impact of obesity and body fat distribution on survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. 
  • Implementation of an Automated Radiology Recommendation-Tracking Engine for Abdominal Imaging Findings of Possible Cancer. 
  • Implications of peritoneal cytology for pancreatic cancer management. 
  • Improved overall survival is still observed in patients receiving delayed adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. 
  • In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. 
  • In vivo and in vitro binding of iodinated monoclonal antibody A2B5 to RIN insulinoma cells. 
  • In vivo and in vitro propagation of intraductal papillary mucinous neoplasms. 
  • Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. 
  • Incidence of benign disease in patients that underwent resection for presumed pancreatic cancer diagnosed by endoscopic ultrasonography (EUS) and fine-needle aspiration (FNA). 
  • Incidentally discovered pancreatic intraepithelial neoplasia: what is its clinical significance? 
  • Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. 
  • Increased myocellular lipid and IGFBP-3 expression in a pre-clinical model of pancreatic cancer-related skeletal muscle wasting. 
  • Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. 
  • Index Symptoms and Prognosis Awareness of Patients With Pancreatic Cancer: A Multi-Site Palliative Care Collaborative. 
  • Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma. 
  • Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. 
  • Induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice. 
  • Induction of ductal and stromal hyperplasia by basic fibroblast growth factor produced by human pancreatic carcinoma. 
  • Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. 
  • Inflammatory mechanisms in diabetes: lessons from the beta-cell. 
  • Inhibiting effect of murine double minute-2 oncogene on apoptosis induced by retroviral-mediated wild-type p53. 
  • Inhibition of Isoprenylcysteine Carboxylmethyltransferase Induces Cell-Cycle Arrest and Apoptosis through p21 and p21-Regulated BNIP3 Induction in Pancreatic Cancer. 
  • Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. 
  • Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis. 
  • Inhibition of endoglin-GIPC interaction inhibits pancreatic cancer cell growth. 
  • Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells. 
  • Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. 
  • Initial experience with neoadjuvant FOLFIRINOX as first line therapy for locally advanced pancreatic cancer. 
  • Initial report of laparoscopic celiac plexus block for pain relief in patients with unresectable pancreatic cancer. 
  • Injectable polypeptide micelles that form radiation crosslinked hydrogels in situ for intratumoral radiotherapy. 
  • Insights into beta cell regeneration for diabetes via integration of molecular landscapes in human insulinomas. 
  • Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells. 
  • Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer. 
  • Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer. 
  • Insulinomas: from diagnosis to treatment. A review of the literature. 
  • Intact nitric oxide synthase II gene is required for interferon-beta-mediated suppression of growth and metastasis of pancreatic adenocarcinoma. 
  • Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. 
  • Intensity modulated radiation therapy reduces gastrointestinal toxicity in locally advanced pancreas cancer. 
  • Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer. 
  • Interobserver agreement for detection of malignant features of intraductal papillary mucinous neoplasms of the pancreas on MDCT. 
  • Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. 
  • Intraductal Oncocytic Papillary Neoplasms: Clinical-Pathologic Characterization of 24 Cases, With An Emphasis on Associated Invasive Carcinomas. 
  • Intraductal Papillary Mucinous Neoplasm of the Pancreas in Young Patients: Tumor Biology, Clinical Features, and Survival Outcomes. 
  • Intraductal Papillary Mucinous Neoplasms and the Risk of Diabetes Mellitus in Patients Undergoing Resection Versus Observation. 
  • Intraductal Papillary Mucinous Neoplasms: Have IAP Consensus Guidelines Changed our Approach?: Results from a Multi-institutional Study. 
  • Intraductal Tubulopapillary Neoplasm of the Pancreas: A Clinicopathologic and Immunohistochemical Analysis of 33 Cases. 
  • Intraductal papillary mucinous neoplasm (IPMN) with extra-pancreatic mucin: a case series and review of the literature. 
  • Intraductal papillary mucinous neoplasm. 
  • Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas? 
  • Intraoperatic electron beam irradiation in pancreatic cancer. 
  • Intraoperative fluid management and complications following pancreatectomy. 
  • Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer. 
  • Invited commentary. 
  • Irreversible Electroporation (IRE) Combined With Chemotherapy Increases Survival in Locally Advanced Pancreatic Cancer (LAPC). 
  • Irreversible electroporation (Nanoknife® treatment) in the field of hepatobiliary surgery: Current status and future perspectives. 
  • Irreversible electroporation in a case of pancreatic leiomyosarcoma: a novel weapon versus a rare malignancy? 
  • Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? 
  • Is there a role for advanced radiation therapy technologies in the treatment of pancreatic adenocarcinoma? 
  • Isoprenylcysteine carboxylmethyltransferase is required for the impact of mutant KRAS on TAZ protein level and cancer cell self-renewal. 
  • K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking. 
  • KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin. 
  • Knockdown of prolactin receptors in a pancreatic beta cell line: effects on DNA synthesis, apoptosis, and gene expression. 
  • Knowledge-based adaptive planning quality assurance using dosimetric indicators for stereotactic adaptive radiotherapy for pancreatic cancer. 
  • LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. 
  • Lack of evidence for MHC-unrestricted (atypical) recognition of mucin by mucinous pancreatic tumour-reactive T-cells. 
  • Lactogenic and somatogenic hormones regulate the expression of neuropeptide Y and cocaine- and amphetamine-regulated transcript in rat insulinoma (INS-1) cells: interactions with glucose and glucocorticoids. 
  • Laparoscopic biliary and enteric bypass. 
  • Laparoscopic distal pancreatectomy: evolution of a technique at a single institution. 
  • Laparoscopic-assisted ERCP and EUS in patients with prior Roux-en-Y gastric bypass surgery: a dual-center case series experience. 
  • Laparoscopy and peripancreatic neoplasia. 
  • Lending a hand for laparoscopic distal pancreatectomy: the optimal approach? 
  • Levels of Alternatively Spliced Tissue Factor in the Plasma of Patients with Pancreatic Cancer May Help Predict Aggressive Tumor Phenotype. 
  • Liberal resection for (presumed) Sendai negative branch-duct intraductal papillary mucinous neoplasms--also not harmless. 
  • Lifestyle, occupational, and reproductive factors in relation to pancreatic cancer risk. 
  • LigAmp for sensitive detection of single-nucleotide differences. 
  • Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors. 
  • Lipid-rich variant of a pancreatic endocrine neoplasm in an endoscopic ultrasound-guided fine needle aspiration biopsy. 
  • Liver standardized uptake value corrected for lean body mass at FDG PET/CT: effect of FDG uptake time. 
  • Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. 
  • Locally advanced pancreatic cancer. 
  • Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. 
  • Long-term Outcomes After Surgical Resection of Pancreatic Metastases from Renal Clear-Cell Carcinoma. 
  • Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer. 
  • Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. 
  • Loss of HNF6 expression correlates with human pancreatic cancer progression. 
  • Loss of microRNA-21 leads to profound stromal remodeling and short survival in K-Ras-driven mouse models of pancreatic cancer. 
  • Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. 
  • Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. 
  • Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression. 
  • Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. 
  • Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. 
  • MDCT evaluation of the pancreas: nuts and bolts. 
  • MR cholangiopancreatography of bile and pancreatic duct abnormalities with emphasis on the single-shot fast spin-echo technique. 
  • Magnetic resonance imaging of the pancreas with gadolinium-DTPA. 
  • Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis. 
  • Malignant biliary obstruction: efficacy of thin-section dynamic CT in determining resectability. 
  • Malignant gastric outlet obstruction: bridging another divide. 
  • Malignant progression in IPMN: a cohort analysis of patients initially selected for resection or observation. 
  • Management of locally advanced adenocarcinoma of the pancreas. 
  • Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. 
  • Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design. 
  • Maximizing Tumor Control and Limiting Complications With Stereotactic Body Radiation Therapy for Pancreatic Cancer. 
  • Measurement of Reactive Oxygen Species by Fluorescent Probes in Pancreatic Cancer Cells. 
  • Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death. 
  • Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. 
  • Meta-analysis: the detection of pancreatic malignancy with positron emission tomography. 
  • Metabolic syndrome and in-hospital outcomes among pancreatic cancer patients. 
  • Metastases in the pancreas from nonhematologic neoplasms: report of 20 cases evaluated by fine-needle aspiration. 
  • Metastatic Merkel cell carcinoma (MCC) of pancreas and breast: a unique case. 
  • Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. 
  • Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. 
  • Metformin Use Is Associated with Improved Survival in Patients Undergoing Resection for Pancreatic Cancer. 
  • Metformin use is associated with better survival of diabetic patients with pancreatic cancer. 
  • MiR-135 suppresses glycolysis and promotes pancreatic cancer cell adaptation to metabolic stress by targeting phosphofructokinase-1. 
  • Mice transgenic for a vasopressin-SV40 hybrid oncogene develop tumors of the endocrine pancreas and the anterior pituitary. A possible model for human multiple endocrine neoplasia type 1. 
  • Minimally Invasive Distal Pancreatectomy for Cancer: Short-Term Oncologic Outcomes in 1,733 Patients. 
  • Minimally Invasive Pancreaticoduodenectomy Does Not Improve Use or Time to Initiation of Adjuvant Chemotherapy for Patients With Pancreatic Adenocarcinoma. 
  • Minimally Invasive Versus Open Pancreaticoduodenectomy for Cancer: Practice Patterns and Short-term Outcomes Among 7061 Patients. 
  • Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. 
  • Molecular and immunochemical analyses of RB1 and cyclin D1 in human ductal pancreatic carcinomas and cell lines. 
  • Molecular characterization of pancreatic neoplasms. 
  • Molecular diagnosis of pancreatic and biliary cancer: ready for broad implementation? 
  • Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. 
  • Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. 
  • Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classification. 
  • Mouse models of metastatic pancreatic adenocarcinoma. 
  • Mucinous cystic tumor of the pancreas: an analysis of FNA characteristics with an emphasis on the spectrum of malignancy associated features. 
  • Multi-institutional Development and External Validation of a Nomogram to Predict Recurrence After Curative Resection of Pancreatic Neuroendocrine Tumors. 
  • Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma. 
  • Multidetector CT of the pancreas and bile duct system: value of curved planar reformations. 
  • Multidimensional Immunophenotyping of Intraductal Papillary Mucinous Neoplasms Reveals Novel T Cell and Macrophage Signature. 
  • Multiinstitutional Validation Study of Cyst Fluid Protein Biomarkers in Patients With Cystic Lesions of the Pancreas. 
  • Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration. 
  • N-cadherin functions as a growth suppressor in a model of K-ras-induced PanIN. 
  • N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate: synthesis and potential utility for the radioiodination of monoclonal antibodies. 
  • NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. 
  • NCCN practice guidelines for pancreatic cancer. 
  • NOTUM is a potential pharmacodynamic biomarker of Wnt pathway inhibition. 
  • National Trends in End-of-Life Care for Veterans With Advanced Cancer in the Veterans Health Administration: 2009 to 2016. 
  • Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis of 18 243 patients. 
  • Natural History of Patients Followed Radiographically with Mucinous Cysts of the Pancreas. 
  • Needle types used in abdominal cross-sectional interventional radiology: a survey of the Society of Abdominal Radiology emerging technology commission. 
  • Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. 
  • Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. 
  • Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. 
  • Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. 
  • New NCCN Guidelines for Locally Advanced Pancreatic Cancer: New Horizons in Extending Resectability. 
  • New applications of gemcitabine and future directions in the management of pancreatic cancer. 
  • New option for the initial management of metastatic pancreatic cancer? 
  • New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts. 
  • Normal flux through ATP-citrate lyase or fatty acid synthase is not required for glucose-stimulated insulin secretion. 
  • Novel approaches to 'borderline resectable' pancreatic tumors. 
  • Novel insulinoma cell lines produced by iterative engineering of GLUT2, glucokinase, and human insulin expression. 
  • Novel therapies for pancreatic adenocarcinoma. 
  • Novel therapies for pancreatic adenocarcinoma. 
  • Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. 
  • Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. 
  • Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. 
  • O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors. 
  • Obesogenic high-fat diet heightens aerobic glycolysis through hyperactivation of oncogenic KRAS. 
  • Obliteration of the fat surrounding the celiac axis and superior mesenteric artery is not a specific CT finding of carcinoma of the pancreas. 
  • Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case-Control Study. 
  • Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. 
  • Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet. 
  • Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity. 
  • Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. 
  • Operative resection is currently overutilized for cystic lesions of the pancreas. 
  • Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity. 
  • Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. 
  • Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in BRCA1 and BRCA2. 
  • Outcomes and tolerability of chemoradiation therapy for pancreatic cancer patients aged 75 years or older. 
  • Outcomes of Lymph Node Dissection for Non-metastatic Pancreatic Neuroendocrine Tumors: A Propensity Score-Weighted Analysis of the National Cancer Database. 
  • Overexpression of G11alpha and isoforms of phospholipase C in islet beta-cells reveals a lack of correlation between inositol phosphate accumulation and insulin secretion. 
  • Overexpression of SOX11 and TFE3 in Solid-Pseudopapillary Neoplasms of the Pancreas. 
  • Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. 
  • Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma. 
  • Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. 
  • Overexpression of synuclein-gamma in pancreatic adenocarcinoma. 
  • Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. 
  • Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. 
  • PEGylated gold nanoparticles conjugated to monoclonal F19 antibodies as targeted labeling agents for human pancreatic carcinoma tissue. 
  • PET-Computed Tomography and Precision Medicine in Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Tumors. 
  • PET/CT of cancer patients: part 1, pancreatic neoplasms. 
  • PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers. 
  • PPDPF Promotes the Development of Mutant KRAS-Driven Pancreatic Ductal Adenocarcinoma by Regulating the GEF Activity of SOS1. 
  • Pain and depression in patients with newly diagnosed pancreas cancer. 
  • Pancreas and liver resection in Jehovah's Witness patients: feasible and safe. 
  • Pancreatic Adenocarcinoma, Version 1.2019. 
  • Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. 
  • Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. 
  • Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. 
  • Pancreatic Cancer Chemoprevention Translational Workshop: Meeting Report. 
  • Pancreatic FNA in 1000 cases: a comparison of imaging modalities. 
  • Pancreatic Fluid Interleukin-1β Complements Prostaglandin E2 and Serum Carbohydrate Antigen 19-9 in Prediction of Intraductal Papillary Mucinous Neoplasm Dysplasia. 
  • Pancreatic Neuroendocrine Tumors. 
  • Pancreatic Safety of Sitagliptin in the TECOS Study. 
  • Pancreatic acinar cell carcinoma: A review on molecular profiling of patient tumors. 
  • Pancreatic adenocarcinoma cell line, MDAPanc-28, with features of both acinar and ductal cells. 
  • Pancreatic adenocarcinoma in a young patient population--12-year experience at Memorial Sloan Kettering Cancer Center. 
  • Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. 
  • Pancreatic adenocarcinoma. 
  • Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology. 
  • Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology. 
  • Pancreatic adenocarcinoma: putting a hump in survival. 
  • Pancreatic adenocarcinoma: the actual 5-year survivors. 
  • Pancreatic cancer mortality in Egypt: comparison to the United States pancreatic cancer mortality rates. 
  • Pancreatic cancer. 
  • Pancreatic cancer: future outlook, promising trials, newer systemic agents, and strategies from the Gastrointestinal Intergroup Pancreatic Cancer Task Force. 
  • Pancreatic cancer: translating lessons from mouse models. 
  • Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas. 
  • Pancreatic cyst fluid concentration of high-mobility group A2 protein acts as a differential biomarker of dysplasia in intraductal papillary mucinous neoplasm. 
  • Pancreatic cyst fluid glucose: rapid, inexpensive, and accurate diagnosis of mucinous pancreatic cysts. 
  • Pancreatic cyst fluid protein expression profiling for discriminating between serous cystadenoma and intraductal papillary mucinous neoplasm. 
  • Pancreatic duct stenosis secondary to small endocrine neoplasms: a manifestation of serotonin production? 
  • Pancreatic duct strictures: identifying risk of malignancy. 
  • Pancreatic ductal adenocarcinoma with autoimmune pancreatitis-like histologic and immunohistochemical features. 
  • Pancreatic gross tumor volume contouring on computed tomography (CT) compared with magnetic resonance imaging (MRI): Results of an international contouring conference. 
  • Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma. 
  • Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma. 
  • Pancreatic islet cell carcinoma associated with multiple hormone secretion and pancytopenia. Evidence of a serum factor suppressing hematopoiesis. 
  • Pancreatic malignancy: effect of dual-phase helical CT in tumor detection and vascular opacification. 
  • Pancreatic metastasectomy: the Memorial Sloan-Kettering experience and a review of the literature. 
  • Pancreatic metastasis from a solitary fibrous tumor of the kidney: a rare cause of acute recurrent pancreatitis. 
  • Pancreatic microcystic adenoma presenting with acute hemoperitoneum: CT diagnosis. 
  • Pancreatic neuroendocrine tumor with cystlike changes: evaluation with MDCT. 
  • Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy. 
  • Pancreatic neuroendocrine tumors: pathologic and molecular characteristics. 
  • Pancreatic panniculitis. 
  • Pancreaticoduodenectomy for the treatment of pancreatic neoplasms in children: A Pediatric Surgical Oncology Research Collaborative study. 
  • Pancreaticoduodenectomy: frequency and outcome of post-operative imaging-guided percutaneous drainage. 
  • Pancreatoblastoma in a teenage patient. 
  • Passive smoking and the use of noncigarette tobacco products in association with risk for pancreatic cancer: a case-control study. 
  • Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality. 
  • Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract: Recommendations of Verona Consensus Meeting. 
  • Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. 
  • Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinations. 
  • Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation. 
  • Peak density of immature nerve cells occurs with high-grade dysplasia in intraductal papillary mucinous neoplasms of the pancreas. 
  • Pentose conversions support the tumorigenesis of pancreatic cancer distant metastases. 
  • Peptide-mediated targeting of the islets of Langerhans. 
  • Percutaneous Peritoneal Lavage for the Rapid Staging of Gastric and Pancreatic Cancer. 
  • Percutaneous biopsy of periarterial soft tissue cuffs in the diagnosis of pancreatic carcinoma. 
  • Performance of the 7 th and 8 th Editions of the American Joint Committee on Cancer Staging System in Patients with Intraductal Papillary Mucinous Neoplasm-Associated PDAC : A Multi-institutional Analysis. 
  • Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. 
  • Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. 
  • Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. 
  • Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. 
  • Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. 
  • Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis. 
  • Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors. 
  • Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. 
  • Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma. 
  • Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. 
  • Phase II study of amonafide in advanced pancreatic adenocarcinoma. 
  • Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. 
  • Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. 
  • Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas. 
  • Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS^G12R -mutant pancreatic ductal adenocarcinoma. 
  • Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. 
  • Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer. 
  • Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. 
  • Phase II trial of curcumin in patients with advanced pancreatic cancer. 
  • Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma. 
  • Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers. 
  • Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. 
  • Pilot phase II trial of 13-cis-retinoic acid and interferon-alpha combination therapy for advanced pancreatic adenocarcinoma. 
  • Pilot study of rapid MR pancreas screening for patients with BRCA mutation. 
  • Pitfalls in avoiding operation for autoimmune pancreatitis. 
  • Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. 
  • Platinum-Based Treatment for Well- and Poorly Differentiated Pancreatic Neuroendocrine Neoplasms. 
  • Pneumoperitoneum complicating ERCP performed immediately after EUS-guided fine needle aspiration. 
  • Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. 
  • Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. 
  • Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. 
  • Polymorphisms of p21 and p27 jointly contribute to an earlier age at diagnosis of pancreatic cancer. 
  • Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. 
  • Portal vein resection during pancreaticoduodenectomy for pancreatic neuroendocrine tumors. An international multicenter comparative study. 
  • Positron emission tomography for the evaluation of pancreatic disease. 
  • Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. 
  • Postoperative complications and overall survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. 
  • Postoperative prognosis prediction of pancreatic cancer with seven microRNAs. 
  • Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. 
  • Potential functional variants in SMC2 and TP53 in the AURORA pathway genes and risk of pancreatic cancer. 
  • Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. 
  • Practice patterns for reporting digestive system neuroendocrine neoplasms: results from a large, comprehensive international survey. 
  • Pre-existing, Concurrent/Early-Onset, and Late-Onset Diabetes in Chronic Pancreatitis: Do Outcomes Differ? 
  • Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study. 
  • Predicting dysplasia and invasive carcinoma in intraductal papillary mucinous neoplasms of the pancreas: development of a preoperative nomogram. 
  • Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG. 
  • Preliminary study of tumor heterogeneity in imaging predicts two year survival in pancreatic cancer patients. 
  • Premalignant cystic neoplasms of the pancreas. 
  • Prenatal diethylstilbestrol exposure and cancer risk in women. 
  • Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. 
  • Preoperative CT predictors of survival in patients with pancreatic ductal adenocarcinoma undergoing curative intent surgery. 
  • Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. 
  • Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. 
  • Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. 
  • Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation. 
  • Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas. 
  • Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. 
  • Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas. 
  • Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. 
  • Preoperative endocrine tumor localization utilizing a cost-effective approach. 
  • Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. 
  • Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. 
  • Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. 
  • Preoperative predictors for complications after pancreaticoduodenectomy: impact of BMI and body fat distribution. 
  • Preoperative risk prediction for intraductal papillary mucinous neoplasms by quantitative CT image analysis. 
  • Primary pancreatic lymphoma evaluated by fine-needle aspiration: findings in 14 cases. 
  • Primary sarcomas of the pancreas: A review of 253 patients from the National Cancer Data Base. 
  • Prognostic Value of FDG PET/CT-Derived Parameters in Pancreatic Adenocarcinoma at Initial PET/CT Staging. 
  • Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). 
  • Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. 
  • Prognostic factors in resectable pancreatic cancer: p53 and bcl-2. 
  • Prognostic impact of RT-PCR-based detection of peritoneal micrometastases in patients with pancreatic cancer undergoing curative resection. 
  • Prognostic indicators following curative pancreatoduodenectomy for pancreatic carcinoma: A retrospective multivariate analysis of a single centre experience. 
  • Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases. 
  • Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. 
  • Prognostic significance of the highest peripancreatic lymph node in biliary tract adenocarcinoma. 
  • Prolactin induction of insulin gene expression: the roles of glucose and glucose transporter-2. 
  • Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. 
  • Prospective evaluation of laparoscopic celiac plexus block in patients with unresectable pancreatic adenocarcinoma. 
  • Proteasome-mediated degradation and functions of hematopoietic progenitor kinase 1 in pancreatic cancer. 
  • Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. 
  • Pylorus-preserving pancreatoduodenectomy. A clinical and physiologic appraisal. 
  • Quality of Life Associated with Open vs Minimally Invasive Pancreaticoduodenectomy: A Prospective Pilot Study. 
  • Quantification of respiration-induced abdominal tumor motion and its impact on IMRT dose distributions. 
  • Quantitative Computed Tomography Image Analysis to Predict Pancreatic Neuroendocrine Tumor Grade. 
  • Quantitative and Qualitative Comparison of Single-Source Dual-Energy Computed Tomography and 120-kVp Computed Tomography for the Assessment of Pancreatic Ductal Adenocarcinoma. 
  • RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704. 
  • Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. 
  • Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas. 
  • Radioiodine and 211At-labeled guanidinomethyl halobenzoyl octreotate conjugates: potential peptide radiotherapeutics for somatostatin receptor-positive cancers. 
  • Radiolocalization of human pancreatic tumors in athymic mice by monoclonal antibody DU-PAN 1. 
  • Radiomic feature reproducibility in contrast-enhanced CT of the pancreas is affected by variabilities in scan parameters and manual segmentation. 
  • Raising the pressure: Hemodynamic effects of splanchnic nerve stimulation. 
  • Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. 
  • Randomized clinical trials in pancreatic adenocarcinoma. 
  • Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. 
  • Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. 
  • Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. 
  • Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. 
  • Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. 
  • Rapid-fractionation pre-operative chemoradiation for malignant periampullary neoplasms. 
  • Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. 
  • Readmission after pancreatic resection: causes and causality pattern. 
  • Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. 
  • Real-time quantitative PCR of telomerase mRNA is useful for the differentiation of benign and malignant pancreatic disorders. 
  • Recurrence and Survival After Resection of Small Intraductal Papillary Mucinous Neoplasm-associated Carcinomas (≤20-mm Invasive Component): A Multi-institutional Analysis. 
  • Recurrence patterns of intraductal papillary mucinous neoplasms of the pancreas on enhanced computed tomography. 
  • Referring Provider Perceptions of Standardized Reporting for Possible Abdominal Cancer. 
  • Regulation of insulin secretion from novel engineered insulinoma cell lines. 
  • Regulation of interleukin-8 expression by cellular pH in human pancreatic adenocarcinoma cells. 
  • Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. 
  • Relationships between sclerosing cholangitis, inflammatory bowel disease, and cancer in patients undergoing liver transplantation. 
  • Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. 
  • Report of the 16th International Symposium of the Foundation for Promotion of Cancer Research: Recent advances in pancreatic cancer. 
  • Resected pancreatic neuroendocrine tumors: patterns of failure and disease-related outcomes with or without radiotherapy. 
  • Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. 
  • Resistance of pancreatic carcinoma cells is reversed by coculturing NK-like T cells with dendritic cells pulsed with tumor-derived RNA and CA 19-9. 
  • Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. 
  • Response to the Comment on "Intraductal Papillary Mucinous Neoplasms: Have IAP Consensus Guidelines Changed Our Approach?: Results From a Multi-institutional Study". 
  • Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study). 
  • Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical Trial. 
  • Risk factors for pancreatic cancer: case-control study. 
  • Robotic-assisted minimally invasive central pancreatectomy: technique and outcomes. 
  • Role of endoscopic retrograde cholangiopancreatography in acute pancreatitis. 
  • Role of lymphadenectomy, adjuvant chemotherapy, and treatment at high-volume centers in patients with resected pancreatic cancer-a distinct view on lymph node yield. 
  • Role of radiation therapy in patients with resectable pancreatic cancer. 
  • Routine intensive care unit admission among patients undergoing major pancreatic surgery for cancer: No effect on failure to rescue. 
  • Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. 
  • SOX9: a useful marker for pancreatic ductal lineage of pancreatic neoplasms. 
  • STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. 
  • Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. 
  • Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. 
  • Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. 
  • Sclerosing mesenteritis involving the pancreas: a mimicker of pancreatic cancer. 
  • Secretin-induced Duodenal Aspirate of Pancreatic Juice (SIDA): Utility of Commercial Genetic Analysis. 
  • Selected polymorphisms of DNA repair genes and risk of pancreatic cancer. 
  • Selective killing of cancer cells harboring mutant RAS by concomitant inhibition of NADPH oxidase and glutathione biosynthesis. 
  • Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. 
  • Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. 
  • Serial EUS-Guided FNA for the Surveillance of Pancreatic Cysts: A Study of Long-Term Performance of Tumor Markers. 
  • Serotonin expression in pancreatic neuroendocrine tumors correlates with a trabecular histologic pattern and large duct involvement. 
  • Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. 
  • Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. 
  • Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer. 
  • Serum biomarker panels for the detection of pancreatic cancer. 
  • Serum cadmium levels in pancreatic cancer patients from the East Nile Delta region of Egypt. 
  • Should Patients With Cystic Lesions of the Pancreas Undergo Long-term Radiographic Surveillance?: Results of 3024 Patients Evaluated at a Single Institution. 
  • Should all branch-duct intraductal papillary mucinous neoplasms be resected? 
  • Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer. 
  • Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. 
  • Significance of pathologic response to preoperative therapy in pancreatic cancer: the future ain't what it used to be. 
  • Significance of peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreatic head. 
  • Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. 
  • Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival. 
  • Simple pancreatic cysts: CT and endosonographic appearances. 
  • Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. 
  • Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. 
  • Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. 
  • Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer. 
  • Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. 
  • Small serotonin-producing neuroendocrine tumor of the pancreas associated with pancreatic duct obstruction. 
  • Small-bowel malabsorption and gastrointestinal malignancy. 
  • Solid Pseudopapillary Neoplasm of the Pancreas in Children and Adults: A National Study of 369 Patients. 
  • Solid pseudo-papillary tumors of the pancreas: current update. 
  • Solid pseudopapillary neoplasm of the pancreas with prominent atypical multinucleated giant tumour cells. 
  • Solid pseudopapillary neoplasm of the pancreas: clinicopathologic and survival analyses of 64 cases from a single institution. 
  • Solid pseudopapillary tumors of the pancreas. Clinical features, surgical outcomes, and long-term survival in 45 consecutive patients from a single center. 
  • Somatostatinoma of the endocrine pancreas: CT findings. 
  • Somatostatinoma: atypical presentation of a rare pancreatic tumor. 
  • Sonic hedgehog signaling pathway supports cancer cell growth during cancer radiotherapy. 
  • Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. 
  • Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts. 
  • Spindle cell stromal tumor of the pancreas: treatment by pancreatoduodenectomy. 
  • Staging chest computed tomography and positron emission tomography in patients with pancreatic adenocarcinoma: utility or futility? 
  • Staging of pancreatic cancer before and after neoadjuvant chemoradiation. 
  • Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. 
  • Stereotactic radiotherapy for pancreatic cancer? 
  • Stimulation of insulin secretion by a rapid intravenous calcium infusion in patients with beta-cell neoplasms of the pancreas. 
  • Sugar pills for pancreatic cancer: the benefits of becoming (insulin) sensitive. 
  • Suppression of pancreatic tumor progression by systemic delivery of a pancreatic-cancer-specific promoter driven Bik mutant. 
  • Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells. 
  • Surgical management of pancreatic lymphoma. 
  • Surgical resection is associated with improved long-term survival of patients with resectable pancreatic head cancer compared to multiagent chemotherapy. 
  • Surgical treatment of resectable and borderline resectable pancreatic cancer: expert consensus statement by Evans et al. 
  • Survival Prediction in Pancreatic Ductal Adenocarcinoma by Quantitative Computed Tomography Image Analysis. 
  • Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. 
  • Survival for Patients with Radiographically Occult Metastatic Pancreatic Cancer in the Era of Modern Multiagent Chemotherapy. 
  • Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. 
  • Synchronous Hemihepatectomy With Pancreatectomy Through Application of Associated Liver Partition and Portal Vein Ligation for a Metastatic Gastrinoma. 
  • Synchronous resection of esophageal cancer and other organ malignancies: A systematic review. 
  • Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. 
  • Synergistic effects of multiple natural products in pancreatic cancer cells. 
  • Synthesis, characterization, and functionalization of gold nanoparticles for cancer imaging. 
  • Synthetic microRNA designed to target glioma-associated antigen 1 transcription factor inhibits division and induces late apoptosis in pancreatic tumor cells. 
  • Systematic Review of Surgical and Percutaneous Irreversible Electroporation in the Treatment of Locally Advanced Pancreatic Cancer. 
  • TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3. 
  • TSPO-targeted PET and Optical Probes for the Detection and Localization of Premalignant and Malignant Pancreatic Lesions. 
  • Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. 
  • Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth. 
  • Targeting cell surface GRP78 enhances pancreatic cancer radiosensitivity through YAP/TAZ protein signaling. 
  • Targeting eNOS in pancreatic cancer. 
  • Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer. 
  • Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers. 
  • Technology evaluation: Rexin-G, Epeius Biotechnologies. 
  • Telomeres are shortened in acinar-to-ductal metaplasia lesions associated with pancreatic intraepithelial neoplasia but not in isolated acinar-to-ductal metaplasias. 
  • Temporal dynamics of Wnt-dependent transcriptome reveal an oncogenic Wnt/MYC/ribosome axis. 
  • The "Nouvelle Vague" of surgeons in pancreatic surgery: can they rise to the legacy of current surgeons? 
  • The CUL7/F-box and WD repeat domain containing 8 (CUL7/Fbxw8) ubiquitin ligase promotes degradation of hematopoietic progenitor kinase 1. 
  • The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients. 
  • The Impact of Cirrhosis on Pancreatic Cancer Surgery: A Systematic Review and Meta-Analysis. 
  • The Interface of Pancreatic Cancer With Diabetes, Obesity, and Inflammation: Research Gaps and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop. 
  • The Oncogenesis in Patients With Pancreatic Intraductal Papillary Mucinous Neoplasms: Taking the Thread From the Beginning. 
  • The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. 
  • The Role of Positron Emission Tomography/Computed Tomography in Management and Prediction of Survival in Pancreatic Cancer. 
  • The Role of Surgery for Pancreatic Neuroendocrine Tumors. 
  • The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk. 
  • The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. 
  • The challenge of pancreatic cancer. 
  • The clinical utility of immunoglobulin G4 in the evaluation of autoimmune pancreatitis and pancreatic adenocarcinoma. 
  • The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting. 
  • The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. 
  • The detection of telomerase activity in patients with adenocarcinoma of the pancreas by fine needle aspiration. 
  • The diagnosis and management of cystic lesions of the pancreas. 
  • The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer. 
  • The efficacy and safety of the open approach irreversible electroporation in the treatment of pancreatic cancer: A systematic review. 
  • The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. 
  • The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. 
  • The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. 
  • The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. 
  • The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy: an analysis of the American College of Surgeons National Surgical Quality Improvement Program database. 
  • The influence of positive peritoneal cytology on survival in patients with pancreatic adenocarcinoma. 
  • The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704. 
  • The management of intraductal papillary mucinous neoplasms of the pancreas. 
  • The need for standardized pathologic staging of pancreaticoduodenectomy specimens. 
  • The novel triad of dorsal agenesis of the pancreas with concurrent pancreatic ductal adenocarcinoma and nonalcoholic chronic calcific pancreatitis: a case series and review of the literature. 
  • The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. 
  • The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes. 
  • The oral microbiota in patients with pancreatic cancer, patients with IPMNs, and controls: a pilot study. 
  • The outcome of resected cystic pancreatic endocrine neoplasms: a case-matched analysis. 
  • The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. 
  • The role of intraoperative radiation therapy in patients with pancreatic cancer. 
  • The role of laparoscopy in the management of suspected pancreatic and periampullary malignancies. 
  • The safety of a pancreaticoduodenectomy in patients older than 80 years: risk vs. benefits. 
  • The subcellular localization of syntaxin 17 varies among different cell types and is altered in some malignant cells. 
  • The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis. 
  • The use of pancreatic ductoscopy in the operative management of benign and malignant pancreatic disorders. 
  • The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas. 
  • The vacuolar-ATPase modulates matrix metalloproteinase isoforms in human pancreatic cancer. 
  • The value of diagnostic aids in detecting pancreas cancer. 
  • The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. 
  • Therapeutic Approach to Cystic Neoplasms of the Pancreas. 
  • Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. 
  • Therapeutic tools in pancreatic cancer. 
  • Therapy of malignant hamster insulinomas with monoamine precursors. 
  • Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. 
  • Three novel genetic variants in NRF2 signaling pathway genes are associated with pancreatic cancer risk. 
  • Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells. 
  • Tobacco Carcinogen-Induced Production of GM-CSF Activates CREB to Promote Pancreatic Cancer. 
  • Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. 
  • Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. 
  • Total robotic pancreaticoduodenectomy: a systematic review of the literature. 
  • Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. 
  • Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. 
  • Transplantation of insulinoma into the diabetic Syrian hamster. 
  • Transplantation of rat insulinoma allografts with cyclosporin A. 
  • Transport properties of pancreatic cancer describe gemcitabine delivery and response. 
  • Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated. 
  • Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX. 
  • Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. 
  • Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes. 
  • Trefoil factor 1 acts to suppress senescence induced by oncogene activation during the cellular transformation process. 
  • Trends in racial disparities in pancreatic cancer surgery. 
  • Triphasic contrast enhanced CT simulation with bolus tracking for pancreas SBRT target delineation. 
  • Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy. 
  • Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. 
  • Tumor suppressor gene Smad4/DPC4, its downstream target genes, and regulation of cell cycle. 
  • Tumor-associated Neutrophils and Malignant Progression in Intraductal Papillary Mucinous Neoplasms: An Opportunity for Identification of High-risk Disease. 
  • Two-dimensional multiplanar and three-dimensional volume-rendered vascular CT in pancreatic carcinoma: interobserver agreement and comparison with standard helical techniques. 
  • Uncinate duct dilation in intraductal papillary mucinous neoplasms of the pancreas: a radiographic finding with potentially increased malignant potential. 
  • Underutilization of surgical resection in patients with pancreatic acinar cell carcinoma. 
  • Unusual finding in a patient with pancreas divisum and abdominal pain. 
  • Unusually high rate of young-onset pancreatic cancer in the East Nile Delta region of Egypt. 
  • Update on combined-modality treatment options for pancreatic cancer. 
  • Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010. 
  • Updates and Critical Evaluation on Novel Biomarkers for the Malignant Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas. 
  • Use of a Noise Optimized Monoenergetic Algorithm for Patient-Size Independent Selection of an Optimal Energy Level During Dual-Energy CT of the Pancreas. 
  • Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth. 
  • Utility of DNA Profiling From Main Pancreatic Duct Fluid by Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography to Screen for Malignant Potential. 
  • Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. 
  • Vascular surgery collaboration during pancreaticoduodenectomy with vascular reconstruction. 
  • Venous Invasion in Pancreatic Neuroendocrine Tumors Is Independently Associated With Disease-free Survival and Overall Survival. 
  • WHipple-ABACUS, a simple, validated risk score for 30-day mortality after pancreaticoduodenectomy developed using the ACS-NSQIP database. 
  • Weight Loss, Diabetes, Fatigue, and Depression Preceding Pancreatic Cancer. 
  • Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas. 
  • Why John wasn't healed by prayer: perspectives across disciplines. 
  • Widespread Repression of Gene Expression in Cancer by a Wnt/β-Catenin/MAPK Pathway. 
  • Widespread activation of the DNA damage response in human pancreatic intraepithelial neoplasia. 
  • Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer. 
  • XRCC2 and XRCC3 gene polymorphism and risk of pancreatic cancer. 
  • Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010. 
  • ZIP4 is a novel diagnostic and prognostic marker in human pancreatic cancer: a systemic comparison between EUS-FNA and surgical specimens. 
  • Zollinger-Ellison syndrome. 
  • [Apoptosis induced by adenovirus-mediated wild-type p53 expression in human pancreatic cancer cells]. 
  • [Fine needle aspiration of pancreatic masses. A study of 81 cases]. 
  • [GIPC: a new target for therapy in pancreatic adenocarcinoma?]. 
  • [Insulin producing cells as therapy in diabetes mellitus]. 
  • [Murine Doube Minute 2 oncogene inhibited apoptosis induced by retroviral-mediated wild-type p53]. 
  • [Studies on MDM2 oncogene expression and its effect on pancreatic carcinoma cells]. 
  • [The effect of adenovirus-mediated wild-type p53 expression on the growth of human pancreatic carcinoma cell line cells]. 
  • [The inhibitory effect of combined treatment of TNF alpha and antisense oligodeoxynucleotides on the growth of human pancreatic carcinoma cell line cells]. 
  • bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. 
  • eIF4E-phosphorylation-mediated Sox2 upregulation promotes pancreatic tumor cell repopulation after irradiation. 
  • miR-301a as an NF-κB activator in pancreatic cancer cells. 
  • p16 Inactivation in pancreatic intraepithelial neoplasias (PanINs) arising in patients with chronic pancreatitis. 
• 

  Keywords of People

  • Abbruzzese, James, D. C. I. Distinguished Professor of Medical Oncology, Medicine, Medical Oncology
  • Jowell, Paul Simon, Professor of Medicine, Medicine, Gastroenterology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Patz Jr., Edward F., James and Alice Chen Distinguished Professor of Radiology, Pathology
  • Reed, Shelby Derene, Professor in Population Health Sciences, Duke Science & Society
  • Stinnett, Sandra Sue, Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Uronis, Hope Elizabeth, Associate Professor of Medicine, Medicine, Medical Oncology